Black Titan (BTTC) vs. Its Rivals Critical Analysis

Black Titan (NASDAQ:BTTC) is one of 48 public companies in the “Services – Computer Programming And Data Processing” industry, but how does it contrast to its peers? We will compare Black Titan to related businesses based on the strength of its valuation, institutional ownership, dividends, earnings, analyst recommendations, risk and profitability.

Analyst Ratings

This is a summary of current ratings for Black Titan and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Black Titan Competitors	100	199	220	12	2.27

As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 113.05%. Given Black Titan’s peers stronger consensus rating and higher possible upside, analysts clearly believe Black Titan has less favorable growth aspects than its peers.

Risk and Volatility

Black Titan has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s peers have a beta of 0.68, meaning that their average share price is 32% less volatile than the S&P 500.

Institutional & Insider Ownership

56.0% of shares of all “Services – Computer Programming And Data Processing” companies are held by institutional investors. 0.7% of Black Titan shares are held by company insiders. Comparatively, 16.3% of shares of all “Services – Computer Programming And Data Processing” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Black Titan and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	-108.60%	-95.64%
Black Titan Competitors	-51.37%	-912.76%	-63.13%

Earnings and Valuation

This table compares Black Titan and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Black Titan	$180,000.00	-$4.71 million	-0.60
Black Titan Competitors	$233.59 million	-$56.16 million	-9.70

Black Titan’s peers have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Black Titan peers beat Black Titan on 8 of the 13 factors compared.

Black Titan Company Profile

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.